Toxys Email Formats

Research Services • Manhattan, New York, United States • 1-10 Employees

Toxys Email Formats

Toxys uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@toxys.com), used 66.7% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@toxys.com	66.7%
{first name}.{last name}	john.doe@toxys.com	33.3%

Key Contact at Toxys

Giel Hendriks

President

Company overview

Headquarters	228 E 45th St, Suite 9E, New York, NY 10017, US
Website	toxys.com
NAICS	5417
Keywords	Stem Cells, Dna Damage Response, Developmental Toxicity Assay, Bac Technologies, Genotoxicity Testing, Mammalian Reporter Assays, Mechanism-Based Toxicology, New Approach Methods, Mechanistic Insight Of Toxicity, Mode-Of-Action Information
Founded	2021
Employees	1-10

About Toxys

Toxys is global leading expert that develops and offers a broad spectrum of unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. Toxys Inc. is a subsidiary in the US with a sales office in New York (NY) and a production facility in Gaithersburg (MD) that focuses on serving clients in North America. We are experts in the fields of genotoxicity, developmental toxicology and mechanistic toxicity testing. We develop assays with the focus on understanding the mode-of-action of toxic compounds. Our ToxTracker® assay accurately identifies direct and indirect genotoxic compounds, ReproTracker® detects developmental toxicity that occurs when differentiating human stem cells, and ToxProfiler™ provides a broad toxicity profile of compounds using high content imaging. Our unique assays provide relevant information to avoid compounds failing at a late stage of development due to unforeseen toxicity. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in drug/compound development, thereby contributing to the development of better medicines and products while reducing the need for animal testing. Every novel chemical that is developed in the pharmaceutical, chemical, cosmetics or food industries must be rigorously tested for human health hazards before being considered safe for marketing. Current in vitro toxicity tests, which are an essential part of compound risk assessment, often suffer from a low predictive value and lack the possibility to provide insight into the mode-of-action of toxic compounds. To address these unmet needs, Toxys offers a diverse portfolio of in vitro assays that provide mode-of-action information on toxic compounds and provide information relevant to human health.